Dr. Junzhong Lin 林俊忠
Chief Physician
Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Colorectal cancer, with a focus on laparoscopic, robotic, and transanal minimally invasive surgery. Specializes in individualized sphincter-preserving surgery for low rectal cancer and multidisciplinary treatment for colorectal cancer liver metastases.
Dr. Lin holds an MD and is a master's supervisor. Trained in the seven-year clinical medicine program at Sun Yat-sen University, Dr. Lin completed a doctoral degree in surgical oncology and served as a visiting scholar at MD Anderson Cancer Center (2015–2016). Working at Sun Yat-sen University Cancer Center since 2007, Dr. Lin has led multiple national and provincial grants, published over 30 papers, and co-authored four professional books.
Name order: in Chinese the family name comes first (Lin Junzhong). Papers usually list the name as Junzhong Lin or Lin J.
Selected publications
94 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Res, 2026 (senior author): PKM2 Lactylation Promotes Colorectal Cancer Vasculogenic Mimicry and Bevacizumab Resistance by Facilitating FOSL1 Super-enhancer Formation. PubMed 41784617
- Langenbecks Arch Surg, 2024 (senior author): A novel circumferential continuous reinforcing suture for anastomosis after laparoscopic resection for rectal cancer and sigmoid cancer: a retrospective case-controlled study. PubMed 39395032
- Autophagy, 2024 (senior author): Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer. PubMed 37615625
- Mol Cancer, 2023 (senior author): A positive feedback circuit driven by m(6)A-modified circular RNA facilitates colorectal cancer liver metastasis. PubMed 38087322
- Cancer Med, 2022 (first author): Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer. PubMed 35466587
- Pathol Oncol Res, 2022 (senior author): The Pathologic Complete Response Ratio of Liver Metastases Represents a Valuable Prognostic Indicator. PubMed 36147656
- Am J Cancer Res, 2022 (senior author): A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases. PubMed 35530285
- Ther Adv Gastroenterol, 2021 (senior author): Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy. PubMed 34987612
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion